Asthma: Quality standard [QS25] – NICE

This quality standard covers diagnosing, monitoring and managing asthma in children, young people and adults. It describes high-quality care in priority areas for improvement. In September 2018, this quality standard was updated in response to an annual review, which identified

Transurethral water jet ablation for lower urinary tract symptoms caused by benign prostatic hyperplasia: Interventional procedures guidance [IPG629] – NICE

Evidence-based recommendations on transurethral water jet ablation for lower urinary tract symptoms caused by benign prostatic hyperplasia in adults. This involves injecting a high-speed jet of water into the prostate to destroy some of the tissue. The evidence on transurethral

Eating disorders: Quality standard [QS175] – NICE

This quality standard covers assessment, treatment, monitoring and care for children, young people and adults with an eating disorder. It describes high-quality care in priority areas for improvement.

Inotuzumab ozogamicin for treating relapsed or refractory B-cell acute lymphoblastic leukaemia: Technology appraisal guidance [TA541] – NICE

Evidence-based recommendations on inotuzumab ozogamicin (Besponsa) for relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukaemia in adults. Inotuzumab ozogamicin is recommended, within its marketing authorisation, as an option for treating relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukaemia

Emergency and acute medical care in over 16s: Quality standard [QS174] – NICE

This quality standard covers the organisation and delivery of emergency and acute medical care in the community and in hospital. It covers adults (16 and over) who seek, or are referred for, emergency NHS care for a suspected or confirmed

Preventing suicide in community and custodial settings: NICE guideline [NG105] – NICE

This guideline covers ways to reduce suicide and help people bereaved or affected by suicides. It aims to: help local services work more effectively together to prevent suicide identify and help people at risk prevent suicide in places where it

Neuropad for detecting preclinical diabetic peripheral neuropathy: Medical technologies guidance [MTG38] – NICE

The case for adopting Neuropad to detect preclinical diabetic peripheral neuropathy is not supported by the evidence. Neuropad detects sub-normal sweating in patients with diabetes but the clinical importance of this in current NHS care pathways is poorly defined. There

Chronic heart failure in adults: Quality standard [QS9] – NICE

This updated quality standard covers assessing, diagnosing and managing chronic heart failure in adults (aged 18 and over). It describes high-quality care in priority areas for improvement.

The Vest for delivering high-frequency chest wall oscillation in people with complex neurological needs: Medtech innovation briefing [MIB159] – NICE

The technology described in this briefing is The Vest. It is intended to deliver high-frequency chest wall oscillation for clearing airways. The focus of this briefing is its use in adults and children with complex neurological needs, such as cerebral palsy and

Pancreatitis: NICE guideline [NG104] – NICE

This guideline covers managing acute and chronic pancreatitis in children, young people and adults. It aims to improve quality of life by ensuring that people have the right treatment and follow-up, and get timely information and support after diagnosis.

Please write to me: writing outpatient clinic letters to patients – Academy of Medical Royal Colleges

Guidance to doctors recommending they write outpatient clinic letters directly to patients and send a copy of the letter to the patient’s general practitioner. The guidance covers general aspects of letter writing and applies to letters sent on paper and

Management of stable angina: (SIGN 151) – Scottish Intercollegiate Guidelines Network

This guideline provides evidence-based recommendations and best practice guidance on the management of patients with stable angina. It covers the investigations necessary to confirm the presence of stable angina, the optimum medical treatment to relieve symptoms and the relative benefits

Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma: Technology appraisal guidance [TA540]

Evidence-based recommendations on pembrolizumab (Keytruda) for treating relapsed or refractory classical Hodgkin lymphoma in adults. Pembrolizumab is not recommended for treating relapsed or refractory classical Hodgkin lymphoma in adults who have had autologous stem cell transplant and brentuximab vedotin. Pembrolizumab

Leadless cardiac pacemaker implantation for bradyarrhythmias: Interventional procedures guidance [IPG626] – NICE

Evidence-based recommendations on leadless cardiac pacemaker implantation for bradyarrhythmias in adults. This involves inserting a device into the heart that helps it beat at a normal rate. Evidence on the safety of leadless cardiac pacemaker implantation for bradyarrhythmias shows that

Superior rectal artery embolisation for haemorrhoids: Interventional procedures guidance [IPG627] – NICE

Evidence-based recommendations on superior rectal artery embolisation for haemorrhoids in adults. This involves blocking the blood vessels supplying the haemorrhoids with tiny plastic particles or metal coils. Current evidence on the safety and efficacy of superior rectal artery embolisation for

Lutetium (177Lu) oxodotreotide for treating unresectable or metastatic neuroendocrine tumours: Technology appraisal guidance [TA539] – NICE

Evidence-based recommendations on lutetium (177Lu) oxodotreotide (Lutathera) for treating unresectable or metastatic neuroendocrine tumours in adults. Lutetium (177Lu) oxodotreotide is recommended, within its marketing authorisation, as an option for treating unresectable or metastatic, progressive, well-differentiated (grade 1 or grade 2), somatostatin receptor-positive

Neon EEG electrode for EEG monitoring in newborns: Medtech innovation briefing [MIB155] – NICE

The technology described in this briefing is Neon EEG electrode. It is used for electroencephalogram (EEG) monitoring in newborns. The innovative aspects are that EEG electrodes can be placed on a newborn, without extra preparation or an EEG technician. The intended place in therapy would be

NephroCheck test to help assess the risk of acute kidney injury in critically ill patients: Medtech innovation briefing [MIB156] – NICE

The technology described in this briefing is the NephroCheck (including VITROS NephroCheck) test. It is an in vitro diagnostic test used to measure urinary biomarkers of kidney injury as an aid in detecting acute kidney injury. The innovative aspects are that NephroCheck is claimed

AlignRT in breast cancer radiotherapy: Medtech innovation briefing [MIB157] – NICE

The technology described in this briefing is the AlignRT patient position monitoring system. This briefing focuses on its use during breast cancer radiation therapy. The innovative aspect is that it may avoid inaccurate treatment by precisely tracking a patient’s position

Rezum for treating benign prostatic hyperplasia: Medtech innovation briefing [MIB158] – NICE

The technology described in this briefing is Rezum, which uses steam to ablate prostate tissue with the aim of improving lower urinary tract symptoms secondary to benign prostatic hyperplasia. The innovative aspects are that the company claims that it is quicker to do than